Spinal Muscular Atrophy (Sma) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Spinal Muscular Atrophy (SMA) is a progressive neurodegenerative disorder characterized by the degeneration and loss of lower [motor [neurons in the anterior horn of the spinal-cord and brainstem nuclei, resulting in progressive muscle weakness and atrophy. SMA is caused by homozygous deletion or mutation of the survival motor neuron 1 (SMN1) gene on chromosome 5q13, leading to deficiency of the survival motor neuron (SMN) protein . It is the most common genetic cause of infant mortality, with an incidence of approximately 1 in 10,000 live births and a carrier frequency of roughly 1 in 50 . [@lefebvre1995]
The disease spectrum spans from severe infantile-onset forms with respiratory failure to mild adult-onset weakness. In recent years, the therapeutic landscape for SMA has been transformed by three approved disease-modifying therapies—nusinersen, onasemnogene abeparvovec, and risdiplam—that directly address the underlying genetic defect, making SMA one of the most successful examples of gene-targeted therapy in [neurodegeneration . [@bennett2019]
Spinal Muscular Atrophy (Sma) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Spinal Muscular Atrophy (SMA) is a progressive neurodegenerative disorder characterized by the degeneration and loss of lower [motor [neurons in the anterior horn of the spinal-cord and brainstem nuclei, resulting in progressive muscle weakness and atrophy. SMA is caused by homozygous deletion or mutation of the survival motor neuron 1 (SMN1) gene on chromosome 5q13, leading to deficiency of the survival motor neuron (SMN) protein . It is the most common genetic cause of infant mortality, with an incidence of approximately 1 in 10,000 live births and a carrier frequency of roughly 1 in 50 . [@lefebvre1995]
The disease spectrum spans from severe infantile-onset forms with respiratory failure to mild adult-onset weakness. In recent years, the therapeutic landscape for SMA has been transformed by three approved disease-modifying therapies—nusinersen, onasemnogene abeparvovec, and risdiplam—that directly address the underlying genetic defect, making SMA one of the most successful examples of gene-targeted therapy in [neurodegeneration . [@bennett2019]
SMA is inherited in an autosomal recessive pattern. The SMN1 gene encodes the full-length survival motor neuron protein, which is ubiquitously expressed in virtually every cell of the body. The SMN protein plays essential roles in the assembly of spliceosomal small nuclear ribonucleoproteins (snRNPs), mRNA splicing, axonal-transport-defects, endocytosis, protein translation, and maintenance of cellular homeostasis . [@foust2009]
The nearly identical SMN2 gene, located in a duplicated region on chromosome 5q13, differs from SMN1 by a critical C-to-T transition in exon 7. [This single nucleotide change disrupts an exonic splicing enhancer, causing the majority (~90%) of SMN2 transcripts to skip exon 7 and produce a truncated, rapidly degraded protein (SMNΔ7). Only approximately 10% of SMN2 transcripts produce the full-length, functional SMN protein](https://pmc.ncbi.nlm.nih.gov/articles/PMC4628728/). The copy number of the SMN2 gene is a key modifier of disease severity: patients with more SMN2 copies generally produce more functional SMN protein and have milder phenotypes. [@martin2022]
Although SMN protein is expressed in all tissues, lower motor neurons are particularly vulnerable to its deficiency. The mechanisms underlying this selective vulnerability include impaired snRNP biogenesis leading to widespread splicing defects, disrupted axonal transport, defective neuromuscular junction (NMJ) maturation, and aberrant mRNA localization in axons. The loss of motor neurons leads to progressive denervation atrophy of skeletal muscles, particularly proximal muscles . [@younger2023]
SMA is classified into five types based on age of onset, maximum motor milestone achieved, and disease severity : [@monine2021]
The most severe form, presenting with decreased fetal movements in utero. Neonates exhibit severe hypotonia, areflexia, facial diplegia, and joint contractures. Respiratory failure occurs early, and life expectancy is typically less than 6 months. Patients usually have only one SMN2 copy . [@cifuentesdiaz2002]
The most common form, accounting for approximately 50-60% of new SMA diagnoses. Onset occurs before 6 months of age. Infants never achieve the ability to sit independently. They present with severe, progressive symmetric muscle weakness, hypotonia ("floppy infant"), poor head control, weak cry, and swallowing difficulties. Without treatment, respiratory failure typically occurs by age 2. [Most patients have two SMN2 copies](https://www.ncbi.nlm.nih.gov/books/NBK1352/).
Onset between 6 and 18 months of age. Children achieve the ability to sit independently but never walk unaided. Progressive proximal weakness, scoliosis, respiratory insufficiency, and joint contractures develop over time. Life expectancy extends into the second or third decade and beyond with supportive care. Patients typically have three SMN2 copies .
Onset after 18 months of age. Children achieve independent ambulation but may progressively lose this ability. Proximal weakness predominates, with difficulty climbing stairs, rising from chairs, and running. Many patients maintain ambulation into adulthood. Life expectancy is near-normal. Patients typically have three to four SMN2 copies .
Onset in the second or third decade of life (mean onset in the mid-30s). Presents with mild proximal weakness. Ambulation is maintained, and respiratory involvement is rare. Life expectancy is normal. Patients typically have four or more SMN2 copies .
SMA occurs worldwide across all ethnic groups. The overall incidence is approximately 1 in 10,000 live births, making it the second most common autosomal recessive disorder after cystic fibrosis. The carrier frequency is approximately 1 in 40 to 1 in 60, varying by ethnicity .
In the United States, the estimated prevalence by type is:
Diagnosis is confirmed by [genetic-testing](/diagnostics/genetic-testing) for homozygous deletion of SMN1 exon 7, which is present in approximately 95% of affected individuals. The remaining 5% have a point mutation on one allele and a deletion on the other .
Additional diagnostic tools include:
Approved by the FDA in December 2016, nusinersen was the first disease-modifying therapy for SMA. It is an antisense oligonucleotide (ASO) that modifies SMN2 pre-mRNA splicing to promote inclusion of exon 7, thereby increasing production of full-length, functional SMN protein. It requires intrathecal (spinal) injection, with four loading doses in the first two months followed by maintenance doses every four months .
Approved by the FDA in May 2019, onasemnogene abeparvovec is a gene replacement therapy using an adeno-associated virus serotype 9 (AAV9) vector to deliver a functional copy of the human SMN1 gene. It is administered as a single intravenous infusion for patients under 2 years of age. Meta-analyses show a survival rate of approximately 95% in treated SMA Type 1 patients, the highest among approved therapies .
Approved by the FDA in August 2020, risdiplam is a small-molecule SMN2 splicing modifier taken orally as a daily liquid formulation. It promotes exon 7 inclusion in SMN2 mRNA transcripts, increasing systemic SMN protein levels in both the central and peripheral nervous systems. Its oral bioavailability and ability to cross the blood-brain-barrier make it particularly practical for long-term treatment .
Real-world evidence and meta-analyses indicate differential efficacy among the three therapies. In Type 1 SMA patients, onasemnogene abeparvovec demonstrates the highest survival rate (~95%), followed by risdiplam (~86%) and nusinersen (~60%). However, outcomes are strongly influenced by age at treatment initiation, with presymptomatic treatment yielding the best results across all therapies .
Next-generation approaches under investigation include:
SMA shares mechanistic features with other motor neuron diseases:
The study of Spinal Muscular Atrophy (Sma) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent advances in Spinal Muscular Atrophy (SMA) have focused on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutic approaches. Key developments include:
| Type | Onset | Motor Milestones |
|------|-------|------------------|
| Type 1 | Birth-6 months | Never sit independently |
| Type 2 | 7-18 months | Never walk independently |
| Type 3 | >18 months | Walk, lose ability over time |
| Type 4 | Adult onset | Mild, ambulatory |